Dog Atopic Dermatitis Long-term Management

Canine atopic dermatitis (allergic skin disease) affects 10-15% of dogs and causes chronic itching, secondary infections, and significant welfare impairment. Modern targeted therapies have transformed management options.

Key Facts

Atopic dermatitis results from immune dysregulation causing hypersensitivity to environmental allergens
Affected breeds include Labrador Retrievers, Golden Retrievers, West Highland White Terriers, and French Bulldogs
Oclacitinib (Apoquel) and lokivetmab (Cytopoint) are targeted therapies providing good itch control with lower side effect profiles than steroids
Allergen-specific immunotherapy remains the only treatment that can modify underlying allergy, not just control symptoms
Secondary bacterial and yeast skin infections are common in atopic dogs and require concurrent treatment

Welfare Considerations

Chronic atopic dermatitis causes persistent itching that disrupts sleep, normal behavior, and quality of life for affected dogs. Constant scratching, chewing, and rubbing produces skin damage, pain, and secondary infections that compound the original welfare harm. Historically managed with immunosuppressive steroids, modern targeted therapies provide excellent itch control with significantly better safety profiles for long-term use. Allergen-specific immunotherapy offers the possibility of reducing the underlying hypersensitivity over time. The welfare goal is achieving a low itch score with minimal medication side effects.

What You Can Do

Pursue diagnosis and treatment early - atopic dermatitis worsens without management and causes unnecessary suffering
Ask your vet about targeted biologics (Cytopoint) or JAK inhibitors (Apoquel) rather than defaulting to steroids
Consider allergen testing and immunotherapy for dogs with moderate-to-severe disease requiring ongoing medication
Monitor for secondary skin infections regularly in atopic dogs - prompt treatment prevents significant discomfort